Neoplastic development in plasma cells

Immunological Reviews

Volumn 194, Issue , 2003, Pages 177-195

  Potter, Michael ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; BIOLOGICAL FACTOR; DIMETICONE; DNA; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1; MYC PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; ONCOPROTEIN; OSTEOCLAST DIFFERENTIATION FACTOR; PRISTANE; PROTEIN BCL 2; PROTEIN BCL XL; RAF PROTEIN; RAS PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

ANIMAL CELL; CELL INTERACTION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CYTOKINE PRODUCTION; DISEASE MODEL; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MICROENVIRONMENT; MOUSE; MULTIPLE MYELOMA; MUTAGENESIS; NONHUMAN; ONCOGENE; PLASMA CELL; PRIORITY JOURNAL; REVIEW; TISSUE SPECIFICITY; TUMOR MODEL;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMA CELLS;

EID: 0038336667     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00061.x     Document Type: Review

References (142)

1. Balazs M, Martin F, Zhou T, Kearney JF. Blood dentritic cells interact with splenic marginal zone B cells to initiate T-independent immune responses. Immunity 2002;17:341-352.
2. Shaffer AL, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity 2002;17:51-62.
3. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000;13:199-212.
4. Calame KL. Plasma cells: finding new light at the end of B cell development. Nature Immunol 2001;2:1103-1108.
5. Oliver AM, Martin F, Gartland GL, Carter RH, Kearney JF. Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol 1997;27:2366-2374.
6. Reimold AM, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature 2001;412:300-307.
7. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med 2002;195:737-745.
8. Manz RA, Lohning M, Cassese G, Thiel A, Radbruch A. Survival of long-lived plasma cells is independent of antigen. Int Immunol 1998;10:1703-1711.
9. Merwin RM, Algire GH. Induction of plasma cell neoplasms and fibrosarcomas in BALB/c mice carrying diffusion chambers. Proc Soc Exp Biol Med 1959;101:437-439.
10. Merwin RM, Redmon LW. Induction of plasma cell tumors and sarcomas in mice by diffusion chambers placed in the peritoneal cavity. J Natl Cancer Inst 1963;31:990-1007.
11. + B cells. Immunol Rev 1994;137:91-118.
12. Kroese FG. Many of the IgA producing plasma cells in murine gut are derived from self-replenishing precursors in the peritoneal cavity. Int Immunol 1989;1:75-84.
13. Rothstein TL, et al. STAT3 activation, chemokine receptor expression, and cyclin-Cdk function in B-1 cells. Curr Top Microbiol Immunol 2000;252:121-130.
14. Deenen GJ, Kroese FGM. Kinetics of peritoneal B-1a cells (CD5 B cells) in young adult mice. Eur J Immunol 1993;23:12-16.
15. Athanassiades TJ, Speirs RS. Formation of antigen-induced granulomas containing plasma cells: a light and electron microscopic study. J Reticuloendothelial Soc 1968;5:485-497.
16. Athanassiades TJ, Speirs RS. Granuloma induction in the peritoneal cavity. A model for the study of inflammation and plasmacytopoiesis in non-lymphatic organs. J Reticuloendothelial Soc 1972;11:60-76.
17. Weinberg DF, Baldo-Correa E, Lenzi HL, Borojevic R. Schistosoma mansoni: peritoneal plasmacytogenesis and polypoid transformation of mesenteric milky spots in infected mice. Exp Parasitol 1992;74:408-416.
18. Potter M, Wax J, Jones GM. Indomethacin is a potent inhibitor of pristane and plastic disc induced plasmacytomagenesis in a hypersusceptible BALB/c congenic strain. Blood 1997;90:260-269.
19. Potter M, Morrison S, Wiener F, Miller FW. Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice. J Natl Cancer Inst 1994;86:1058-1065.
20. Takakura K, Mason WB, Hollander VP. Studies on the pathogenesis of plasma cell tumors. I. Effect of cortisol on development of plasma cell tumors. Cancer Res 1966;26:596-599.
21. Nordan RP, Potter M. A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986;233:566-569.
22. Hinson RM, Williams JA, Shacter E. Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: possible role of cyclooxygenase-2. Proc Natl Acad Sci USA 1996;93:4885-4890.
23. Potter M, Mushinski EB, Wax JS, Hartley J, Mock BA. Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice. Cancer Res 1994;54:969-975.
24. Janz S, Muller J, Shaughnessy J, Potter M. Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction. Proc Natl Acad Sci USA 1993;90:7361-7365.
25. Roschke V, Kopantzev E, Dertzbaugh M, Rudikoff S. Chromosomal translocations deregulating c-myc are associated with normal immune responses. Oncogene 1997;14:3011-3016.
26. Amoroso SR, Huang N, Roberts AB, Potter M, Letterio JJ. Consistent loss of functional type beta transforming growth factor receptor expression in murine plasmacytomas. Proc Nad Acad Sci USA 1998;95:189-194.
27. Fernandez T, et al. Disruption of transforming growth factor beta signaling by a novel ligand-dependent mechanism. J Exp Med 2002;195:1247-1255.
28. Muller JR, Jones GM, Potter M, Janz S. Detection of immunoglobulin/c-myc recombinations in mice that are resistant to plasmacytoma induction. Cancer Res 1996;56:419-423.
29. Muller JR, Jones GM, Janz S, Potter M. Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice. Blood 1997;89:291-296.
30. Hickman JA. Apoptosis and tumourigenesis. Curr Opin Genet Dev 2002;12:67-72.
31. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood 1993;82:3712-3720.
32. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S. Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 1999;18:5268-5677.
33. Vaux DL, Adams JM, Alexander WS, Pike BL. Immunologic competence of B cells subjected to constitutive c-myc oncogene expression in immunoglobulin heavy chain enhancer myc transgenic mice. J Immunol 1987;139:3854-3860.
34. Evan GI, Littlewood TD. The role of c-myc in cell growth. Curr Opin Genet Dev 1993;3:44-49.
35. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001;411:342-348.
36. Evan G, Littlewood T. A matter of life and cell death. Science 1998;281:1317-1322.
37. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogemc properties of Myc and triggers carcinogenic progression. Cell 2002;109:321-334.
38. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell 1999;4:199-207.
39. Mock BA, Krall MM, Dosik JK. Genetic mapping of tumor susceptibility genes involved in mouse plasmacytomagenesis. Proc Natl Acad Sci USA 1993;90:9499-9503.
40. Zhang S, Ramsay ES, Mock BA. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr 1. Proc Natl Acad Sci USA 1998;95:2429-2434.
41. Zhang SL, et al. Efficiency alleles of the Pctr1 modifier locus for plasmacytoma susceptibility. Mol Cell Biol 2001;21:310-318.
42. Zhang S, et al. p16INK4a gene promoter variation and differential binding of a repressor, the ras responsive zinc finger transcription factor, RREB. Oncogene 2003;22:2285-2295.
43. Sviderskaya EV, et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 2002;94:446-454.
44. Namba Y, Hanaoka M. Immunocytology of cultured IgM-forming cells of mouse. I. Requirement of phagocytic cell factor for the growth of IgM-forming tumor cells in tissue culture. J Immunol 1972;109:1193-1200.
45. Namba Y, Hanaoka M. Immunocytology of cultured IgM-forming cells of mouse. II. Purification of phagocytic cell factor and its role in antibody formation. Cell Immunol 1974;12:74-84.
46. Metcalf D. Colony formation in agar by murine plasmacytoma cells: potentiation by hemopoietic cells and serum. J Cell Physiol 1973;81:397-410.
47. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.
48. Billian A. Growth and differentiation Factors. In: Melchers F, Potter M, eds. Mechanisms of B Cell Neoplasia. Basle: Editiones Roche 1987, 87-90.
49. Lansdorp PM, Aarden LA, Calafat J, Zeiljemaker WP. A growth-factor dependent B-cell hybridoma. Curr Top Microbiol Immunol 1986;132:105-113.
50. Van Sinck J, Vink A, Cayphas S, Uyttenhove C. Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med 1987;165:641-649.
51. Potter M, Pumphrey JG, Walters JL. Growth of primary plasmacytomas in the mineral oil-conditioned peritoneal environment. J Natl Cancer Inst 1972;49:305-308.
52. Hilbert DM, Kopf M, Mock BA, Kohler G, Rudikoff S. Interleukin 6 is essential for in vivo development of B lineage neoplasms. J Exp Med 1995;182:243-248.
53. Degrassi A, Hilbert DM, Rudikoff S, Anderson AO, Potter M, Coon HG. In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc Natl Acad Sci USA 1993;90:2060-2064.
54. Vink A, et al. Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor. J Exp Med 1990;172:997-1000.
55. Van Riet I, et al. Establishment and characterization of a human stroma-dependent myeloma cell line (MM5.1) and its stroma-independent variant (MM5.2). Leukemia 1997;11:284-293.
56. Le J, Reis LF, Vilcek J. Tumor necrosis factor and interleukin 1 can act as essential growth factors in a routine plasmacytoma line. Lymphokine Res 1988;7:99-106.
57. Chatterjee M, et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002;100:3311-3318.
58. Jego G. interleukin-6 is a growth factor for non-malignant human plasmablasts. Blood 2001;97:1817-1822.
59. Lattanzio G, et al. Defective development of pristane-oil-induced plasmacytomas m interleukin-6-deficient BALB/c mice. Am J Pathol 1997;151:689-696.
60. Chin L, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999;400:468-472.
61. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell lenkaemia induced by BCR-ABL1. Nat Genet 2000;24:57-60.
62. Clynes R, Wax J, Stanton LW, Smith-Gill S, Potter M, Marcu KB. Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus. Proc Natl Acad Sci USA 1988;85:6067-6071.
63. Troppmair J, Potter M, Wax JS, Rapp UR. An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis. Proc Natl Acad Sci USA 1989;86:9941-9945.
64. Potter M, et al. Avian v-myc replaces chromosomal translocation in murine plasmacytomagenesis. Science 1987;235:787-789.
65. Rosenbaum H, et al. An E-mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene. EMBO J 1990;9:897-905.
66. Potter M, Sklar MD, Rowe WP. Rapid viral reduction of plasmacytomas in pristane-primed BALB-c mice. Science 1973;182:592-594.
67. Sugiyama H, Weber G, Silva S, Babonits M, Wiener F, Klein G. The accelerating role of Abelson murine leukemia virus in murine plasmacytoma development: in vitro infection of spleen cells generates donor-type tumors after transfer to pristane-treated BALB/c mice. Int J Cancer 1989;44:348-352.
68. Ohno S, et al. Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and abelson virus. J Exp Med 1984;159:1762-1777.
69. Largaespada DA, et al. A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas. Oncogene 1992;7:811-819.
70. Weissinger EM, Byrd LG, Henderson DW, Mushinski JF. Overexpression of v-abl uniquely cooperates with c-myc dysregulation in induction of plasma cell tumors, bypassing the need for T-lymphocytic help and overcoming T-lymphocytic interference. Int J Cancer 1996;67:142-147.
71. Smith JM, Mayer BJ. Abl: mechanisms of regulation and activation. Front Biosci 2002;7:d31-42.
72. Suematsu S, et al. IgG1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989;86:7547-7551.
73. Suematsu S, et al. Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice. Proceedings of the Natl Acad Sci USA, 1992;89:232-235.
74. Schirmacher P, et al. Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice. Am J Pathol 1998;153:639-648.
75. Woodroofe C, Muller W, Ruther U. Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol 1992;11:587-592.
76. Kovalchuk AL, et al. IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci USA 2002;99:1509-1514.
77. Strasser A, Harris AW, Cory S. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. Oncogene 1993;8:1-9.
78. Silva S, Klein G. Plasmacytoma induction in specific pathogen-free (SPF) bcl-2 transgenic BALB/c mice. Curr Top Microbiol Immunol 1999;246:379-385.
79. Hickman ES, Moroni MC, Helin K. The role of p53 and pRB in apoptosis and cancer. Curr Opin Genet Dev 2002;12:60-66.
80. + tonsillar plasma cells are rescued from apoptosis by bone marrow fibroblasts. J Exp Med 1996;183:227-236.
81. Jourdan M, De Vos J, Mechti N, Klein B. Regulation of Bcl-2-family proteins in myeloma cells by three myeloma survival factors: interleukin-6, interferon-alpha and insulin-like growth factor 1. Cell Death Differ 2000;7:1244-1252.
82. Eischen CM, et al. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1. Oncogene 2001;20:6983-6993.
83. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
84. McDonnell TJ, et al. bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989;57:79-88.
85. Fang W, et al. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity 1996;4:291-299.
86. Fang W, et al. Self-reactive B lymphocytes overexpressing Bcl-xL escape negative selection and are tolerized by clonal anergy and receptor editing. Immunity 1998;9:35-45.
87. Grillot DA, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med 1996;183:381-391.
88. Radl J, Hollander CF. Homogeneous immunoglobulins in sera of mice during aging. J Immunol 1974;112:2271-2273.
89. Radl J, de Glopper E, van den Berg P, van Zwieten MJ. Idiopathic paraproteinemia. III. Increased frequency of paraproteinemia in thymectomized aging C57BL/KaLwRij and CBA/BrARij mice. J Immunol 1980;125:31-35.
90. van den Akker TW, grondijk R, Radl J. Influence of long-term antigenic stimulation started in young C57BL mice on the development of age-related monoclonal gammapathies. Int Arch Allergy Appl Immunol 1988;87:165-170.
91. van den Akker TW. The influence of T cells on homogeneous immunoglobulins in sera of athymic nude mice during aging. Scand J Immunol 1988;28:359-365.
92. Radl J, De Glopper ED, Schuit FIR, Zurcher C. Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing done from old to young C57BL/KaLwRij mice. J Immunol 1979;122:609-613.
93. Radl J. Animal model of human disease. Benign monoclonal gammopathy (idiopathic paraproteinemia). Am J Pathol 1981;105:91-93.
94. Manning LS, Berger JD, O'Donoghue HL, Sheridan GN, Claringbold PG, Turner JH. A model of multiple myeloma: culture of 5T33 murine myeloma cells and evaluation of tumorigenicity in the C57BL/KaLwRij mouse. Br J Cancer 1992;66:1088-1093.
95. Croese JW, Vas Nunes CM, Radl J, van den Enden-Vieveen MH, Brondijk RJ, Boersma WJ. The 5T2 mouse multiple myeloma model: characterization of 5T2 cells within the bone marrow. Br J Cancer 1987;56:555-560.
96. Radl J, et al. The 5T mouse multiple myeloma model: absence of c-myc oncogene rearrangement in early transplant generations. Br J Cancer 1990;61:276-278.
97. Asosingh K, Gunthert U, De Raeve H, Van Riet I, Van Camp B, Vanderkerken K. A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res 2001;61:2862-2865.
98. Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Rev Clin Exp Hematol 2002;6:225-252.
99. Slifka MK, Matloubian M, Ahmed R. Bone marrow is a major site of long-term antibody production after acute viral infection. J Virol 1995;69:1895-1902.
100. Garant PR, Paik KS, Cho MI. The distribution of plasma cells in naturally occurring periodontitis lesions in rats. A light and electron microscopic study. J Periodontol 1983;54:227-235.
101. Fayette J, et al. Dendritic cells enhance die differentiation of naïve B cells into plasma cells in vitro. Scan J Immunol 1998;48:563-570.
102. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 1997;80:1538-1545.
103. Compston JE. Bone marrow and bone: a functional unit. J Endocrinol 2002;173:387-394.
104. Valentin-Opran A, Charhon SA, Meunier PJ, Edouard CM, Arlot ME. Quantitative histology of myeloma-induced bone changes. Br J Haematol 1982;52:601-610.
105. Croucher PI, Apperley JF. Bone disease in multiple myeloma. Br J Haematol 1998;103:902-910.
106. Oyajobi BO, Mundy GR. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1 alpha, and the proteasome. Cancer 2003;97:813-817.
107. Menten P, Wuyts A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev 2002;13:455-481.
108. Choi SJ, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671-675.
109. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-3533.
110. Roux S, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002;117:86-92.
111. Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer 2003;97:802-812.
112. Croucher PI, et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 2001;98:3534-3540.
113. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK hgand and osteoprotegerin in myeloma bone disease. Blood 2003;101:2094-2098.
114. Sezer O, Heider U, Jakob C, Eucker J, Possinger K. Human bone marrow myeloma cells express RANKL. J Clin Oncol 2002;20:353-354.
115. Sezer O, et al. hnmunocytochemistry reveals RANKL expression of myeloma cells. Blood 2002;99:4646-4647.
116. Klein B. Cytokine, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma. Semin Hematol 1995;32:4-19.
117. Barille S, Collette M, Bataille R, Amiot M. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995;86:3151-3519.
118. Barille S, Bataille R, Amiot M. The role of interleukin-6 and interleukin-6/interleukin-6 receptor-alpha complex in the pathogenesis of multiple myeloma. Eur Cytokine Netw 2000;11:546-551.
119. Zkang XG, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood 1994;83:3654-3663.
120. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-2011.
121. Caligaris-Cappio F, Gregoretti MG, Ghia P, Bergui L. In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol Oncol Clin North Am 1992;6:257-271.
122. Urashima M, et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997;90:754-765.
123. McCune JM. Development and applications of the SCID-hu mouse model. Semin Immunol 1996;8:187-196.
124. Yaccoby S, Barlogie B, Epstein J. Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998;92:2908-2913.
125. Yaccoby S, Epstein J. The proliferative potential of myeloma plasma cells manifest in the SCID-hu host. Blood 1999;94:3576-3582.
126. Foulds L. Neoplastic Development. New York: Academic Press 1969.
127. Potter M, Boyce C. Induction of plasma cell neoplasms in strain BALB/c mice with mineral oil and mineral oil adjuvants. Nature 1962;193:1086-1087.
128. Anderson PN, Potter M. Induction of plasma cell tumours in BALB-c mice with 2,6,10,14-tetramethylpentadecane (pristane). Nature 1969;222:994-995.
129. Anderson PN. Plasma cell tumor induction in BALB/c mice. Proc Am Assoc Cancer Res 1970;11:3-3.
130. Potter M, Wax JS. Peritoneal plasmacytomagenesis in mice: comparison of different pristane dose regimens. J Natl Cancer Inst 1983;71:391-395.
131. Potter M, Robertson CL. Development of plasma-cell neoplasms in BALB/c mice after intraperitoneal injection of paraffin-oil adjuvant, heat-killed staphylococcus mixtures. J Natl Cancer Inst 1960;25:847-861.
132. Warner NL. Autoimmunity and the pathogenesis of plasma cell tumor induction in NZB and hybrid mice. Immunogenetics 1975;2:1-20.
133. Potter M, Wax JS. Genetics of susceptibility to pristane-induced plasmacytomas in BALB/cAn: reduced susceptibihty in BALB/cJ with a brief description of pristane-induced arthritis. J Immunol 1981;127:1591-1595.
134. Potter M. Genetics of susceptibility to plasmacytoma development in BALB/c mice. Cancer Surv 1984;3:247-264.
135. Potter M, Wax JS, Anderson AO, Nordan RP. Inhibition of plasmacytoma development in BALB/c mice by indomethacin. J Exp Med 1985;161:996-1012.
136. Byrd LG, McDonald AH, Gold LG, Potter M. Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane. J Immunol 1991;147:3632-3637.
137. Mandel MA, DeCosse JJ. The effects of heterologous anti-thymocyte sera in mice. V. Enhancement of plasma cell tumor induction. J Immunol 1972;109:360-365.
138. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin 6 expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990;86:592-599.
139. Kovalchuk AL, Mushinski EB, Janz S. Clonal diversification of primary BALB/c plasmacytomas harboring T(12;15) chromosomal translocations. Leukemia 2000;14: 909-921.
140. Cory S. Activation of cellular oncogenes in hematopoietic cells by chromosome translocation. Adv. Cancer Res. 1986;47:189-216.
141. Cory S, Graham M, Webb E, Corcoran L, Adams JM. Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene. EMBO J 1985;4:675-681.
142. Bazin H, Pear WS, Sumegi J. Louvain rat immunocytomas. Adv. Cancer Res 1988;50:279-310.